A detailed history of Barlow Wealth Partners, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Barlow Wealth Partners, Inc. holds 47,572 shares of VRTX stock, worth $18.9 Million. This represents 2.79% of its overall portfolio holdings.

Number of Shares
47,572
Previous 47,009 1.2%
Holding current value
$18.9 Million
Previous $23.1 Billion 7.5%
% of portfolio
2.79%
Previous 3.19%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$460.0 - $505.78 $258,980 - $284,754
563 Added 1.2%
47,572 $21.3 Billion
Q2 2024

Jul 31, 2024

BUY
$392.81 - $485.53 $312,676 - $386,481
796 Added 1.72%
47,009 $23.1 Billion
Q1 2024

Apr 18, 2024

BUY
$407.69 - $446.08 $508,389 - $556,261
1,247 Added 2.77%
46,213 $18.3 Billion
Q4 2023

Feb 06, 2024

BUY
$343.0 - $410.68 $15.4 Million - $18.5 Million
44,966 New
44,966 $18.3 Billion

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $102B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Barlow Wealth Partners, Inc. Portfolio

Follow Barlow Wealth Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barlow Wealth Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Barlow Wealth Partners, Inc. with notifications on news.